Chemistry:Calderasib

From HandWiki

Calderasib is an investigational new drug that is being developed by Merck Sharp & Dohme for the treatment of solid tumors. It targets tumors that express G12C mutated KRAS protein.[1][2][3]

It has been awarded a breakthrough therapy designation by the U.S. Food and Drug Administration.[4]

References

  1. ↑ "Calderasib". AdisInsight. Springer Nature Switzerland AG. https://adisinsight.springer.com/drugs/800065784. 
  2. ↑ "Discovery of MK-1084: An Orally Bioavailable and Low-Dose KRASG12C Inhibitor". Journal of Medicinal Chemistry 67 (13): 11024–11052. July 2024. doi:10.1021/acs.jmedchem.4c00572. PMID 38924388. 
  3. ↑ "KRAS G12C-mutant non-small cell lung cancer: A practical guide for clinicians". Cancer Treatment Reviews 147. June 2026. doi:10.1016/j.ctrv.2026.103144. PMID 42114275. 
  4. ↑ "FDA Grants Breakthrough Therapy Designation for Calderasib (MK-1084), an Investigational KRAS G12C Inhibitor, for Certain Patients with Newly Diagnosed Metastatic KRAS G12C-Mutant Non-Small Cell Lung Cancer (NSCLC)". Merck & Co., Inc. 2026-05-29. https://www.merck.com/news/fda-grants-breakthrough-therapy-designation-for-calderasib-mk-1084-an-investigational-kras-g12c-inhibitor-for-certain-patients-with-newly-diagnosed-metastatic-kras-g12c-mutant-non-small-cell-lung/. 



Retrieved from "https://handwiki.org/wiki/index.php?title=Chemistry:Calderasib&oldid=4582743"